US-based antibody research company KaloBios Pharmaceuticals, backed by corporate venturing units of Japan-based conglomerate Mitsubishi and US-based healthcare company Genzyme, filed for its initial public offering with the SEC, in which it is seeking $60m.
Stockholders in the US-based company include MPM BioVentures (17.72%), Sofinnova Ventures (11.86%), Alloy Ventures (11.19%), and Fidelity Ventures (9.71%).
In 2008, the firm raised $12m in a series D round, with backing from corporate venturing units Genzyme Venturesand Mitsubishi UFJ Capital as well as venture firms MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Ventures, Singapore Bio-Innovations and 5AM Ventures.
KaloBios raised $20.3m in revenue during 2011, and a further $6m in the first six months of 2012. According to the firm’s S-1, it has $29.7m in total assets as of the end of June this year.
The Calif.-based firm said how much it would be seeking per share was not yet determined, nor was the number of shares it is looking to offer. Leerink Swann is serving as sole book-running manager, with William Blair & Company serving as the lead manager and Needham & Company will serve as co-manager.
When president and chief executive officer David Pritchard announced this summer that KaloBios would file its IPO in the next twelve months, he told news provider the San Francisco Business Times that the company required funds to pursue trials.